Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22103066 | 0.75 | ANPEP (0.60) | ANPEPLAP3 | |
| SCHEMBL21190520 | 0.75 | ANPEP (0.60) | ANPEPLAP3 | |
| SCHEMBL20633200 | 0.71 | ANPEP (0.55) | ANPEPLAP3 | |
| SCHEMBL24526101 | 0.71 | ANPEP (0.55) | ANPEPLAP3 | |
| SCHEMBL20234933 | 0.71 | ANPEP (0.55) | ANPEPLAP3 | |
| SCHEMBL23969659 | 0.71 | ANPEP (0.55) | ANPEPLAP3 | |
| SCHEMBL20755854 | 0.71 | ANPEP (0.55) | ANPEPLAP3 | |
| SCHEMBL22005279 | 0.71 | ANPEP (0.55) | ANPEPLAP3 | |
| SCHEMBL21019857 | 0.71 | ANPEP (0.55) | ANPEPLAP3 | |
| SCHEMBL10937279 | 0.71 | ANPEP (0.55) | ANPEPLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213091-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220047725-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-02-17 | — | — | US | disclosed |
| US-11203591-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210115037-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115037-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | ANPEP 3461/4885LAP3 4231/4885 |
| US-20220047725-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | DAXX, DCAF15, CDY1; CDY1B | ANPEP 1022/4885LAP3 275/4885 |
| US-11203591-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | ANPEP 3461/4885LAP3 4231/4885 |
| US-20220213091-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | ANPEP 3461/4885LAP3 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.